跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AAV-DMD
首页
药物
AAV-DMD
AAV-DMD
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
PREVENTION OF MUSCULAR DYSTROPHY BY CRISPR/CAS9-MEDIATED GENE EDITING
申请人: UNIV TEXAS
优先权: 2014
CN
EP
US
WO
5 件公开
ONE-STEP GENE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY VIA GENE REPLACEMENT AND ANTI-INFLAMMATION
申请人: UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION
优先权: 2019
CN
EP
US
WO
5 件公开
PREVENTION OF MUSCULAR DYSTROPHY BY CRISPR/CPF1-MEDIATED GENE EDITING
申请人: UNIV TEXAS
优先权: 2016
CN
EP
US
WO
4 件公开
COMBINATION THERAPY FOR TREATING MUSCULAR DYSTROPHY
申请人: SOLIDUS BIOSCIENCES INC
优先权: 2018
CN
EP
US
WO
4 件公开
DNA sequences comprising dystrophin minigenes and methods of use thereof
申请人: ASKLEPIOS BIOPHARMACEUTICAL IN
优先权: 2001
US
4 件公开
DMD REPORTER MODELS CONTAINING HUMANIZED DUSCHENE MUSCULAR DYSTROPHY MUTATIONS
申请人: UNIV TEXAS
优先权: 2016
EP
US
WO
3 件公开
AAV-MEDIATED HOMOLOGY-INDEPENDENT TARGETED INTEGRATION GENE EDITING FOR CORRECTION OF DIVERSE DMD MUTATIONS IN PATIENTS WITH MUSCULAR DYSTROPHY
申请人: RES INST NATIONWIDE CHILDRENS HOSPITAL
优先权: 2020
EP
US
WO
3 件公开
PRODUCTS AND METHODS FOR TREATMENT OF DYSTROPHIN-BASED MYOPATHIES USING CRISPR-CAS9 TO CORRECT DMD EXON DUPLICATIONS
申请人: RES INST NATIONWIDE CHILDRENS HOSPITAL
优先权: 2021
EP
US
WO
3 件公开
AAV Expression Cassette and AAV Vectors Comprising the Same
申请人: EXONICS THERAPEUTICS INC
优先权: 2019
US
WO
2 件公开
VIRAL PARTICLES RETARGETED TO SKELETAL MUSCLE
申请人: REGENERON PHARMA
优先权: 2022
CN
US
2 件公开
第 1 / 3 页
上一页
下一页
药物
反馈